COMMUNIQUÉS West-GlobeNewswire

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering
06/06/2025
Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are exercised for cash Xilio may elect to cancel unexercised Series B or Series C warrants [...]
Hydro One et la Fondation ACT célèbrent la formation de plus de 25 000 élèves aux techniques de secourisme
05/06/2025
LINDSAY, Ontario, 05 juin 2025 (GLOBE NEWSWIRE) -- Aujourd’hui, la Fondation des soins avancés en urgence coronarienne (ACT) s’est jointe à Hydro One Inc. (Hydro One) et à ses partenaires de l’école secondaire I.E. [...]
Hydro One and ACT Foundation celebrate more than 25,000 students trained in lifesaving skills
05/06/2025
LINDSAY, Ontario, June 05, 2025 (GLOBE NEWSWIRE) -- Today, the Advanced Coronary Treatment (ACT) Foundation joined Hydro One Inc. (Hydro One) and partners at I.E. Weldon Secondary School in Lindsay to mark the milestone [...]
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/06/2025
REDWOOD CITY, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting [...]
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05/06/2025
NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX ), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1, 2025 the Company [...]
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05/06/2025
CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today [...]
AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™
05/06/2025
VALENCIA, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the first clinical [...]
Hapbee Announces Shares-for-Debt Settlement
05/06/2025
VANCOUVER, British Columbia, June 05, 2025 (GLOBE NEWSWIRE) -- Hapbee Technologies , Inc. (TSXV: HAPB ) (OTCQB: HAPBF) (FSE: HA1) (“ Hapbee ” or the “ Company ”), the digital wellness technology company, announces that [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
05/06/2025
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 05 juin 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
Monthly information on share capital and company voting rights
05/06/2025
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, June 05, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Vireo Growth Inc. Announces Closing of Proper Brands Acquisition in Missouri
05/06/2025
MINNEAPOLIS , June 05, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), today announced that it has closed its previously-announced transaction to acquire Missouri-based [...]
ImPact Biotech Announces Treatment of First Patient in Phase 1 Clinical Trial of Padeliporfin VTP in Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma (PDAC)
05/06/2025
– Previously inoperable patient converted to eligible for resection, underwent pancreaticoduodenectomy, following single course of treatment with Padeliporfin VTP – TEL AVIV, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- [...]
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
05/06/2025
SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with [...]
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/06/2025
BEDFORD, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention [...]
Dentsply Sirona Prices Offering of $550 million of Junior Subordinated Notes
05/06/2025
CHARLOTTE, N.C., June 05, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced it has priced an offering (the “Offering”) of $550 million aggregate principal [...]
Merus N.V. annonce la fixation du prix de l’offre publique d’actions ordinaires
05/06/2025
UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 05 juin 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), ci-après « Merus », la « Société », « nous » ou « notre/nos », une société spécialisée dans l’oncologie [...]
Valneva annonce des résultats positifs de Phase 2 à six mois sur la persistance des anticorps et l’innocuité de son vaccin à dose unique contre le chikungunya IXCHIQ® chez les enfants
05/06/2025
IXCHIQ ® a été bien toléré par les enfants âgés d’un à onze ans indépendamment de la dose de vaccin reçue (dose complète ou demi-dose) ou d’une précédente infection au virus du chikungunya Les niveaux d’anticorps [...]
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®
05/06/2025
IXCHIQ ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high after six months in both dose groups, although more robust [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
05/06/2025
Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 5 juin 2025 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général [...]

Pages